FDA approves new drug for schizophrenia, major depression

July 13, 2015
U.S. FDA approves new drug for schizophrenia, major depression
Medication can be used as an add-on therapy to antidepressants.

(HealthDay)—A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration.

Rexulti (brexpiprazole) tablets can be used to treat adults with . The new drug can also be used as an add-on therapy to for adults with .

"Schizophrenia and can be disabling and can greatly disrupt day-to-day activities," Dr. Mitchell Mathis, director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"Medications affect everyone differently so it is important to have a variety of treatment options available for patients with mental illnesses," he added.

The FDA's approval of Rexulti for treatment of schizophrenia is based on two six-week clinical trials with more than 1,300 people. People taking the drug had fewer symptoms of schizophrenia than those who took a placebo, the studies found.

Rexulti was also tested as an add-on therapy for major depression. For this treatment, researchers conducted two six-week clinical trials. The trials included more than 1,000 patients whose symptoms were not adequately treated by taking an antidepressant alone. Those who took Rexulti and an antidepressant had fewer symptoms of depression than those who took a placebo and an antidepressant, the FDA said.

Weight gain and a sense of restlessness were the most common side effects reported by patients taking Rexulti. The drug is made by Otsuka Pharmaceutical Company Ltd. in Japan.

Like other , Rexulti has a boxed warning about an increased risk of death associated with unapproved use of the drugs to treat behavioral problems in people with dementia-related psychosis.

The boxed warning also cautions about an increased risk of and behavior in children, teens and young adults taking antidepressants. People taking the drug should be monitored for the start or worsening of suicidal thoughts and behavior, the FDA said.

Explore further: First generic Abilify approved

More information: The U.S. National Institute of Mental Health has more about schizophrenia.

Related Stories

First generic Abilify approved

April 30, 2015
(HealthDay)—The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder.

Brintellix approved for major depressive disorder

October 1, 2013
(HealthDay)—Brintellix (vortioxetine) has been approved by the U.S. Food and Drug Administration to treat adults with major depressive disorder, often referred to as depression.

FDA approves new drugs for irritable bowel syndrome

May 28, 2015
(HealthDay)—Two new drugs for adults with irritable bowel syndrome with diarrhea (IBS-D) were approved by the U.S. Food and Drug Administration on Wednesday.

Antidepressant-suicide link in youths absent in new analysis

February 6, 2012
In 2004, concerns about antidepressant drugs increasing suicidal thoughts and behaviors in young patients prompted the FDA to issue a rare "black box warning." Now, a new analysis of clinical trial data finds that treatment ...

FDA OKs new anti-clotting drug for heart rhythm disorder

January 9, 2015
(HealthDay)—A new anti-clotting drug to reduce the risk of dangerous blood clots and strokes in people with a type of heart rhythm disorder has been approved by the U.S. Food and Drug Administration.

FDA weighs removing bolded warning from Chantix

October 14, 2014
(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Recommended for you

Drug overdose epidemic has been growing exponentially for decades

September 20, 2018
Death rates from drug overdoses in the U.S. have been on an exponential growth curve that began at least 15 years before the mid-1990s surge in opioid prescribing, suggesting that overdose death rates may continue along this ...

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Probiotic use may reduce antibiotic prescriptions, researchers say

September 14, 2018
Use of probiotics is linked to reduced need for antibiotic treatment in infants and children, according to a review of studies that probed the benefits of probiotics, say researchers in the U.S., England and the Netherlands.

Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

Sugar pills relieve pain for chronic pain patients

September 12, 2018
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.